CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [81]
In the citing paper
“but correlations between in vivo CSF tau biomarkers and tau aggregates in postmortem tissue are weaker (11).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [11]
In the citing paper
“levels of CSF tau and phosphorylated tau (ptau) species are elevated in DAT8, 13, 14 and are hypothesized to reflect the presence of neurofibrillary tangles and/or neurodegeneration,15, 16 although not all studies support this conclusion.17”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [16]
Citations
Cites
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“A staging system of Alzheimer’s-associated neurofibrillary pathology using immunohistochemistry and AT8 has been suggested (Braak et al., 2006).”
BackgroundMethodSelf-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2×
“Whereas NFTs and neuritic processes are composed of fibrils containing phosphorylated tau, plaques consist mostly of fibrillous beta-amyloid (Grundke-Iqbal et al., 1986; Lee et al., 1991; Dickson, 1997).”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 4×
“CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease Katharina Buerger,1,* Michael Ewers,1,* Tuula Pirttilä,2 Raymond Zinkowski,4 Irina Alafuzoff,3 Stefan J. Teipel,1 John DeBernardis,4 Daniel Kerkman,4 Cheryl McCulloch,4 Hilkka Soininen2 and Harald Hampel1 1Deme…”
BackgroundMethodResultInfluentialSelf-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Cited by
Items 101–200 of 584
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 184
Caroli, A., & Frisoni, G. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.024 · Cited by 148
Giacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11055-5 · Cited by 147
Imbalance of Circulating Th17 and Regulatory T Cells in Alzheimer’s Disease: A Case Control Study
Oberstein, T. J., Taha, L., Spitzer, P., Hellstern, J., Herrmann, M., Kornhuber, J., & Maler, J. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01213 · Cited by 146
van Rossum, I. A., Vos, S., Handels, R., & Visser, P. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091606 · Cited by 145
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI
Ewers, M., Buerger, K., Teipel, S. J., Scheltens, P., Schröder, J., Zinkowski, R. P., Bouwman, F. H., Schönknecht, P., Schoonenboom, N. S. M., Andreasen, N., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000286944.22262.ff · Cited by 146
Self-citationDiagnosis and biomarkers of predementia in Alzheimer's disease
Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-89 · Cited by 145
Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L.-O., SarrÃa, A., & Serrano-Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 142
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 156
Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142
Becker, R. E., Greig, N. H., & Giacobini, E. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15213 · Cited by 140
Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 135
Self-citationHampel, H., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 135
Self-citationAmyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Brewer, J. B., Aisen, P. S., Sperling, R. A., Dale, A. M., & Alzheimer's Disease Neuroimaging Initiative, F. T. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3354 · Cited by 136
Mattsson-Carlgren, N., Grinberg, L. T., Boxer, A., Ossenkoppele, R., Jonsson, M., Seeley, W., Ehrenberg, A., Spina, S., Janelidze, S., Rojas-Martinex, J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200040 · Cited by 128
Sabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B., & Sperling, R. A. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr348 · Cited by 133
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Zhou, Y., Liyanage, P. Y., Devadoss, D., Rios Guevara, L. R., Cheng, L., Graham, R. M., Chand, H. S., Al-Youbi, A. O., Bashammakh, A. S., El-Shahawi, M. S., et al. (2019) · Nanoscale · doi:10.1039/c9nr08194a · Cited by 129
Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A. R., Abraham, R., Hollingworth, P., Harold, D., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001101 · Cited by 128
“Elevated CSF tau levels are associated with neuronal damage and are also observed in stroke [22] and traumatic brain injury immediately after injury [23], however increases in CSF ptau181 levels appear to be specific to AD [24–26].”
BackgroundMattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 129
Leuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology · doi:10.1212/wnl.0000000000012727 · Cited by 128
Hoy, A. R., Ly, M., Carlsson, C. M., Okonkwo, O. C., Zetterberg, H., Blennow, K., Sager, M. A., Asthana, S., Johnson, S. C., Alexander, A. L., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173982 · Cited by 125
Meyer, P.-F., Pichet Binette, A., Gonneaud, J., Breitner, J. C. S., Villeneuve, S., & ADNI Investigators (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4749 · Cited by 124
Potential Bidirectional Relationship Between Periodontitis and Alzheimer’s Disease
Liccardo, D., Marzano, F., Carraturo, F., Guida, M., Femminella, G. D., Bencivenga, L., Agrimi, J., Addonizio, A., Melino, I., Valletta, A., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00683 · Cited by 157
Ewers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119
Self-citationThe BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
Franzmeier, N., Rubinski, A., Neitzel, J., Ewers, M., (ADNI), T. A. D. N. I., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09564-5 · Cited by 109
Self-citationIdentifying incipient dementia individuals using machine learning and amyloid imaging
Mathotaarachchi, S., Pascoal, T. A., Shin, M., Benedet, A. L., Kang, M. S., Beaudry, T., Fonov, V. S., Gauthier, S., & Rosa-Neto, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.027 · Cited by 118
Dronse, J., Fliessbach, K., Bischof, G. N., von Reutern, B., Faber, J., Hammes, J., Kuhnert, G., Neumaier, B., Onur, O. A., Kukolja, J., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160316 · Cited by 117
Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., & Bronfman, F. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r115.053330 · Cited by 117
Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Roddey, J. C., Blennow, K., Aisen, P. S., Brewer, J. B., Hyman, B. T., & Dale, A. M. (2011) · Annals of Neurology · doi:10.1002/ana.22509 · Cited by 118
Upcoming Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease
Fagan, A. M., & Perrin, R. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.42 · Cited by 117
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 114
Ramakers, I. H. G. B., Verhey, F. R. J., Scheltens, P., Hampel, H., Soininen, H., Aalten, P., Rikkert, M. O., Verbeek, M. M., Spiru, L., Blennow, K., et al. (2013) · Psychological Medicine · doi:10.1017/s0033291712001870 · Cited by 115
Self-citationStomrud, E., Hansson, O., Minthon, L., Blennow, K., Rosén, I., & Londos, E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.025 · Cited by 126
Frantzidιs, C. A., Vivas, A. B., Tsolaki, A., Klados, M. A., Tsolaki, M., & Bamidis, P. D. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00224 · Cited by 119
Engelborghs, S., Sleegers, K., Cras, P., Brouwers, N., Serneels, S., De Leenheir, E., Martin, J.-J., Vanmechelen, E., Van Broeckhoven, C., & De Deyn, P. P. (2007) · Brain · doi:10.1093/brain/awm136 · Cited by 113
Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease
Madav, Y., Wairkar, S., & Prabhakar, B. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.004 · Cited by 111
The effect of insomnia on development of Alzheimer’s disease
Sadeghmousavi, S., Eskian, M., Rahmani, F., & Rezaei, N. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01960-9 · Cited by 133
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Self-citationZhao, Y., Xin, Y., Meng, S., He, Z., & Hu, W. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.014 · Cited by 105
Brain Atrophy in Healthy Aging Is Related to CSF Levels of Aβ1-42
Fjell, A. M., Walhovd, K. B., Fennema-Notestine, C., McEvoy, L. K., Hagler, D. J., Holland, D., Blennow, K., Brewer, J. B., Dale, A. M., & Initiative, T. A. D. N. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp279 · Cited by 105
Biochemical Markers in Alzheimer’s Disease
Rabbito, A., Dulewicz, M., Kulczyńska-Przybik, A., & Mroczko, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061989 · Cited by 104
Kam, K., Parekh, A., Sharma, R. A., Andrade, A., Lewin, M., Castillo, B., Bubu, O. M., Chua, N. J., Miller, M. D., Mullins, A. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0309-5 · Cited by 100
Petrie, E. C., Cross, D. J., Galasko, D., Schellenberg, G. D., Raskind, M. A., Peskind, E. R., & Minoshima, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.59 · Cited by 100
Leoni, V. (2011) · cclm · doi:10.1515/cclm.2011.088 · Cited by 100
Biomarkers in dementia with Lewy bodies: a review
Sinha, N., Firbank, M., & O'Brien, J. T. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2749 · Cited by 101
Rates of Decline in Alzheimer Disease Decrease with Age
Holland, D., Desikan, R. S., Dale, A. M., McEvoy, L. K., & Initiative, F. T. A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042325 · Cited by 99
Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98
Ewers, M., Insel, P., Jagust, W. J., Shaw, L., Trojanowski J, J. Q., Aisen, P., Petersen, R. C., Schuff, N., Weiner, M. W., & (ADNI), F. T. A. D. N. I. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr271 · Cited by 97
Self-citationBiomarker-based dissection of neurodegenerative diseases
Olsson, B., Zetterberg, H., Hampel, H. J., & Blennow, K. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.006 · Cited by 108
Self-citationMitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease
Cha, M.-Y., Cho, H. J., Kim, C., Jung, Y. O., Kang, M. J., Murray, M. E., Hong, H. S., Choi, Y.-J., Choi, H., Kim, D. K., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv358 · Cited by 100
“In an AD mouse model that produces large amounts of human amyloid beta (Aβ), mitochondrial dysfunction is apparent before plaque formation (18), and cultured embryonic hippocampal neurons from an AD mousemodel showdecreased respirationand increased glycolysis (19).”
BackgroundComparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
Mattsson, N., Smith, R., Strandberg, O., Palmqvist, S., Schöll, M., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004887 · Cited by 95
Current understanding of chronic traumatic encephalopathy
Baugh, C. M., Robbins, C. A., Stern, R. A., & McKee, A. C. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0306-5 · Cited by 94
Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias
Turner, R. S., Stubbs, T., Davies, D. A., & Albensi, B. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00496 · Cited by 94
Aluise, C. D., Sowell, R. A., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 94
A SERS-Based Sandwich Assay for Ultrasensitive and Selective Detection of Alzheimer’s Tau Protein
Zengin, A., Tamer, U., & Çaykara, T. (2013) · Biomacromolecules · doi:10.1021/bm400968x · Cited by 104
Głodzik-Sobańska, L., Pirraglia, E., Bryś, M., Santi, S. D., Mosconi, L., Rich, K. E., Switalski, R., Louis, L. S., Sadowski, M. J., Martiniuk, F. T., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.019 · Cited by 95
Self-citationEndo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Sjödin, S., Brinkmalm, G., Öhrfelt, A., Parnetti, L., Paciotti, S., Hansson, O., Hardy, J., Blennow, K., Zetterberg, H., & Brinkmalm, A. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0533-9 · Cited by 90
Hu, W. T., Chen-Plotkin, A., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M., McCluskey, L., Elman, L., Karlawish, J., Hurtig, H. I., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0723-9 · Cited by 91
Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers
Barten, D. M., Cadelina, G. W., Hoque, N., DeCarr, L. B., Guss, V. L., Yang, L., Sankaranarayanan, S., Wes, P. D., Flynn, M. E., Meredith, J. E., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110161 · Cited by 90
Alcolea, D. A., Vilaplana, E., Pegueroles, J., Montal, V., Sánchez‐Juan, P., González‐Suárez, A., Pozueta, A., Rodríguez‐Rodríguez, E., Bartrés‐Faz, D., Dídac Vidal-piñeiro, A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.03.001 · Cited by 99
Cerebrospinal Fluid Aβ42, Phosphorylated Tau181, and Resting-State Functional Connectivity
Wang, L., Brier, M. R., Snyder, A. Z., Thomas, J. B., Fagan, A. M., Xiong, C., Benzinger, T. L., Holtzman, D. M., Morris, J. C., & Ances, B. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3253 · Cited by 88
Quantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
Lobello, K., Ryan, J. M., Liu, E., Rippon, G., & Black, R. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/628070 · Cited by 87
EEG time signature in Alzheimer´s disease: Functional brain networks falling apart
Smailovic, U., Koenig, T., Laukka, E. J., Kalpouzos, G., Andersson, T., Winblad, B., & Jelic, V. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.102046 · Cited by 84
White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease
Soldan, A., Pettigrew, C., Zhu, Y., Wang, M.-C., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E., DeCarli, C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008864 · Cited by 84
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 85
Selective Disruption of the Cerebral Neocortex in Alzheimer's Disease
Desikan, R. S., Sabuncu, M. R., Schmansky, N. J., Reuter, M., Cabral, H. J., Hess, C. P., Weiner, M. W., Biffi, A., Anderson, C. D., Rosand, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012853 · Cited by 86
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 84
Initiative, F. T. A. D. N., Takahashi, H., Klein, Z. A., Bhagat, S. M., Kaufman, A. C., Kostylev, M. A., Ikezu, T., & Strittmatter, S. M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1668-z · Cited by 83
Harari, O., Cruchaga, C., Kauwe, J. S. K., Ainscough, B. J., Bales, K., Pickering, E. H., Bertelsen, S., Fagan, A. M., Holtzman, D. M., Morris, J. C., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.032 · Cited by 82
Leko, M. B., Perković, M. N., Klepac, N., Štrac, D. Š., Borovečki, F., Pivac, N., Hof, P. R., & Šimić, G. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200056 · Cited by 87
Advances in nanomedicines for diagnosis of central nervous system disorders
Zhang, X., Zhou, J., Gu, Z., Zhang, H., Gong, Q., & Luo, K. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120492 · Cited by 85
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.027 · Cited by 84
Starks, E. J., Patrick O’Grady, J., Hoscheidt, S. M., Racine, A. M., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Puglielli, L., Asthana, S., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150072 · Cited by 78
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Pradeepkiran, J. A., Baig, J., Islam, M. A., Kshirsagar, S., & Reddy, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0286 · Cited by 102
Chang, C.-Y., Chen, S.-M., Lu, H.-E., Lai, S.-M., Lai, P.-S., Shen, P.-W., Chen, P.-Y., Shen, C.-I., Harn, H.-J., Lin, S.-Z., et al. (2015) · Scientific Reports · doi:10.1038/srep08744 · Cited by 78
Tau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77
Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 88
Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment
Mattsson, N., Portelius, E., Rolstad, S., Gustavsson, M., Andreasson, U., Stridsberg, M., Wallin, A., Blennow, K., & Zetterberg, H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120019 · Cited by 76
Nanoparticle-mediated approaches for Alzheimer’s disease pathogenesis, diagnosis, and therapeutics
Hettiarachchi, S. D., Zhou, Y., Seven, E., Lakshmana, M. K., Kaushik, A. K., Chand, H. S., & Leblanc, R. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.034 · Cited by 76
Weaver, N. A., Doeven, T., Barkhof, F., Biesbroek, J. M., Groeneveld, O. N., Kuijf, H. J., Prins, N. D., Scheltens, P., Teunissen, C. E., van der Flier, W. M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.001 · Cited by 71
“While some neuropathological studies showed a relation between higher CSF p-tau levels and cortical tau pathology (Buerger et al., 2006; Tapiola et al., 2009), these are contested by an equal number of negative studies (Buerger et al.”
ResultMollenhauer, B., Parnetti, L., Rektorová, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W., Aarsland, D., Svenningsson, P., Farotti, L., Verbeek, M. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13390 · Cited by 80
Guzman, V. A., Carmichael, O. T., Schwarz, C., Tosto, G., Zimmerman, M. E., Brickman, A. M., & Initiative, A. D. N. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.009 · Cited by 74
Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
Prvulovic, D., & Hampel, H. (2011) · cclm · doi:10.1515/cclm.2011.087 · Cited by 73
Self-citationNeuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease
Skogseth, R., Mulugeta, E., Ballard, C., Rongve, A., Nore, S., Alves, G., & Aarsland, D. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000137671 · Cited by 71
Potential Long-Term Consequences of Concussive and Subconcussive Injury
Huber, B. R., Alosco, M. L., Stein, T. D., & McKee, A. C. (2016) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2015.12.007 · Cited by 87
A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes
Lleó, A., Irwin, D. J., Illán-Gala, I., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0118 · Cited by 71
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
Holland, D., McEvoy, L. K., Desikan, R. S., Dale, A. M., & Initiative, F. T. A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047739 · Cited by 71
Ossenkoppele, R., Mattsson, N., Teunissen, C. E., Barkhof, F., Pijnenburg, Y., Scheltens, P., van der Flier, W. M., & Rabinovici, G. D. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.011 · Cited by 72
Jellinger, K. A., Janetzky, B., Attems, J., & Kienzl, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00313.x · Cited by 86
The innate immune system in Alzheimer's disease
Boutajangout, A., & Wisniewski, T. (2013) · International Journal of Cell Biology · doi:10.1155/2013/576383 · Cited by 69
“A recent large GWAS study has shown that the Trem2 R47H variant has a strong association with both elevated CSF tau and ptau levels [41].”
BackgroundNübling, G., Bader, B., Levin, J., Hildebrandt, J., Kretzschmar, H., & Giese, A. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-35 · Cited by 69
Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease
Mattsson, N., Schott, J. M., Hardy, J., Turner, M. R., & Zetterberg, H. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311321 · Cited by 69
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 79
Alcolea, D., Martínez-Lage, P., Izagirre, A., Clerigué, M., Carmona-Iragui, M., Alvarez, R. M., Fortea, J., Balasa, M., Morenas-Rodríguez, E., Lladó, A., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131334 · Cited by 67
CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
Rosenmann, H. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9665-5 · Cited by 78
Irwin, D. J., Lleó, A., Xie, S. X., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2017) · Annals of Neurology · doi:10.1002/ana.24996 · Cited by 67
CSF Biomarkers: Pinpointing Alzheimer Pathogenesis
Mattsson, N., Blennow, K., & Zetterberg, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04944.x · Cited by 66
Metadata
- Authors
- Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., & Hampel, H.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Kuopio University Hospital (FI)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-29
- Volume
- 129
- Issue
- 11
- Pages
- 3035-3041
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145450560
- Cited by
- 586
- References
- 33
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 38 · 2020: 40 · 2019: 44 · 2018: 34 · 2017: 31 · 2016: 27 · 2015: 39 · 2014: 34 · 2013: 33 · 2012: 43
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, p-tau231, cerebrospinal fluid biomarkers, neurofibrillary tangles, neuritic plaques, neocortex, frontal cortex, hippocampus, postmortem neuropathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Frontal Lobe, Hippocampus, Humans, Male, Parietal Lobe, Phosphorylation, Temporal Lobe, Biomarkers, Neurofibrillary Tangles, tau Proteins, Neocortex, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.